NEWS

The Health Problem We Address

Chronic diseases represent one of the fastest-growing health challenges globally. Increasing evidence now links gut health and nutrition to the prevention, management and potential reversal of many chronic conditions.

Consumers are actively seeking:

·       Natural, food-based health solutions

·       Products with credible scientific backing

·       Safe options that can be used alongside conventional treatments

This demand now extends beyond digestive health to include metabolic health, inflammation and cognitive decline, including dementia.

The MediKane Solution

MediKane develops Food as Medicine products that deliver therapeutic nutrition in clinically appropriate dosages.

Key characteristics:

·       Food-registered (not supplements)

·       Scientifically formulated and tested

·       Supported by over 13 years of research

·       Independent validation through institutions including Royal Melbourne Hospital and Macquarie University

·       Designed to deliver measurable outcomes quickly

·       No known side effects

MediKane products are intended to complement pharmaceutical and lifestyle therapies, not replace them.

Scientific & Competitive Advantage

MediKane’s differentiation lies in formulation science, ingredient quality and clinical intent.

·       Unique fibre-based ingredients and proprietary formulations

·       High efficacy outcomes across a broad user base

·       Can be used safely alongside prescription medications

·       Positioned as nutrition therapy rather than general supplementation

Unlike many gut health supplements, MediKane products are designed for functional outcomes, not wellness positioning alone.

Market Landscape

MediKane operates within the Natural Health Products and Nutraceuticals sector.

·       The global natural health market was valued at USD 85 billion in 2025, with strong long-term growth driven by plant-based, clean-label and science-backed solutions.

·       The digestive and gut health category alone was valued at USD 18.4 billion in 2024, reflecting growing consumer awareness of the gut’s role in whole-body health.

Growth drivers include:

·       An ageing population

·       Rising prevalence of chronic disease

·       Increased consumer demand for preventative health solutions

Target Customers

Primary customers include:

·       Women aged 35–65+ seeking to age well and extend healthspan

·       Individuals managing or seeking to prevent chronic conditions, particularly:

o   Diabetes

o   Gut and bowel disorders

o   Cognitive health decline

Secondary customers include healthcare practitioners and institutional settings.

Routes to Market

MediKane operates a diversified distribution model, including:

·       Direct-to-consumer (online)

·       Health food stores and pharmacies

·       Healthcare and medical channels (including hospitals and aged care)

·       White-label partnerships (human and pet applications)

·       International distribution, including Asia-Pacific markets

This multi-channel approach reduces dependency on any single route to market.

Traction & Operating History

·       Over 12 years of operating experience

·       Proven repeat purchase behaviour driven by efficacy and product acceptance

·       Established domestic and international distribution experience

·       Demonstrated ability to operate through:

o   Supply chain disruption

o   The COVID-19 pandemic

o   Capital-constrained environments

MediKane has refined its operating model while maintaining product integrity and customer loyalty.

Intellectual Property & Defensibility

MediKane’s position is protected through a combination of formal IP and proprietary know-how:

·       Application patents at PCT stage (including Diabetes and Coeliac Disease)

·       Additional patents in preparation across:

o   Auto-immune disease

o   Inflammation

o   Women’s and pregnancy health

·       Trade secrets and formulation know-how

·       Registered trademarks and brand assets

Why MediKane, Why Now

Several structural and market shifts align strongly with MediKane’s platform:

·       Ageing populations seeking longevity-focused health solutions

·       Increased awareness of gut health’s role in metabolic and cognitive conditions

·       Rising interest in nutrition support alongside GLP-1 therapies

·       Improved supply chain following transition to a high-quality, sustainable fibre supplier

·       Accelerating demand for simple, effective, clinically grounded gut health products

MediKane is now positioned to scale with the right capital and execution support.

Investment Snapshot

·       Unlisted Australian public company

·       No institutional investors currently on the cap table

·       Clean capital structure

·       Clear pathway for growth and strategic exit

·       Opportunities for active investor involvement, including board participation

Indicative investment terms are available on request.